TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05533372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral administration.
Study: NCT05533372
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate for oral administration.
Study: NCT05952375
Drug: Chimeric antigen receptor T cell preparation targeting Claudin18.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor T cell preparation targeting Claudin18.2
Study: NCT05917145
Drug: WSD0628
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
Study: NCT05830539
Drug: IN10018+PLD
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W
Study: NCT04913090
Drug: Placebo to match XZP-5610 Tablet (for Part A)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily for 1 Day
Study: NCT04913090
Drug: Placebo to match XZP-5610 Tablet (for Part B)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily for 14 Days
Study: NCT04913090
Drug: XZP-5610 Tablet （for Part C1）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered fasted orally once daily for 1 Day
Study: NCT04733547
Drug: Replacement of fluid loss after graft procurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
Study: NCT06548971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
Study: NCT05657639
Drug: CAV Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
Study: NCT05657639
Drug: MEC Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
Study: NCT05069740
Drug: Salsalate Pill
Normalized name: salsalate Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
Study: NCT05069740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the salsalate intervention
Study: NCT04818229
Drug: Placebo-matched CBP-307
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matched CBP-307 capsules oral administration.
Study: NCT05066672
Drug: matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo oral capsules
Study: NCT05767086
Drug: Gonadotropin releasing hormone antagonist (Cetrotide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical pregnancy rates
Study: NCT05029999
Drug: PLD Chemotherapy
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
Study: NCT05105061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of matching placebo
Study: NCT06188975
Drug: DRUG: ABBV-CLS-484
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06674252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06675500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Normal saline 0.9 followed by starch oral tablets
Study: NCT06675851
Drug: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
Study: NCT06681012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
Study: NCT06687759
Drug: [14C]MK-1084
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06691243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to placebo arm will receive placebo injection every week.
Study: NCT06627595
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated in accordance with the guidelines for melanoma treatment.
Study: NCT06504966
Drug: Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 60 mg
Study: NCT05365880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active placebo comparator will be provided to participant.
Study: NCT06089317
Drug: TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Study: NCT06089317
Drug: TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)
Normalized name: Houttuynia cordata top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Study: NCT06089317
Drug: Placebo TCM ultrasonic atomization treatment (PA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Study: NCT05381753
Drug: Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
Study: NCT04020263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Study: NCT06289582
Drug: [F-18]DPA714 administration IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: brain PET/MRI imaging after \[F-18\]DPA-714 administration
Study: NCT04781972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04822883
Drug: RL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Study: NCT04822883
Drug: RL-007 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Study: NCT00450840
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06498180
Drug: Glucocorticoid Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
Study: NCT05631886
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
Study: NCT06318546
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
Study: NCT05430919
Drug: REGN5714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05430919
Drug: REGN5715
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06203847
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
Study: NCT06203847
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
Study: NCT06494644
Drug: AZD6793
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
Study: NCT05531942
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
Study: NCT06498531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Study: NCT05323734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT05593770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study: NCT05289908
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
Study: NCT06540209
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will be give Saccharomyces boulardii for 5 days
Study: NCT06540209
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc will be given to all children for 5 days
Study: NCT06643013
Drug: XBD173
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks treatment
Study: NCT06638970
Drug: Secretome
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml Injection of secretome for 4 times two weeks apart
Study: NCT06171802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily for six months
Study: NCT06101667
Drug: Best medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
Study: NCT05474859
Drug: XT-0528
Normalized name: XT-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Daily
Study: NCT05535972
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
Study: NCT05752032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term follow-up
Study: NCT06066099
Drug: AP31969
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06066099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06673238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06686914
Drug: Placebo Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oil, 1 dose
Study: NCT06687083
Drug: nasal continuous positive pressure ventilation mode
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
Study: NCT05691361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline
Study: NCT06439771
Drug: YL202 should be intravenously infused
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Study: NCT06519994
Drug: Placebo vaginal inserts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.
Study: NCT05494619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
Study: NCT05494619
Drug: Intravenous immunoglobulin therapy
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
Study: NCT06570460
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with orally administered estrogen for 6 months
Study: NCT06570460
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with transdermally administered estrogen for 6 months
Study: NCT04810676
Drug: CKD-501, D745, D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05303857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo once weekly
Study: NCT06311734
Drug: LW231 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT06311734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT06443242
Drug: Standard Medication Management (Control Group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Study: NCT05568147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: When patients are randomized into the placebo group, they will receive placebo orally once a day.
Study: NCT04969120
Drug: Placebo (0.9 sodium chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
Study: NCT05646693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
Study: NCT06454084
Drug: Acetylcholine Chloride
Normalized name: Acetylcholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator solution
Study: NCT04980859
Drug: Zebutinib&BR or Zebutinib&FCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
Study: NCT06639672
Drug: Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study: NCT06639672
Drug: Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study: NCT06641219
Drug: One single intravenous injection of [177Lu]Lu-BQ7876
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
Study: NCT05888922
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study: NCT05888922
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study: NCT06565013
Drug: Cabenuva 600/900
Normalized name: Cabenuva 600/900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
Study: NCT06174779
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT06174779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT05392452
Drug: Standard insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy according to local clinical practice.
Study: NCT04878471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT05504746
Drug: SHEN26 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used.
Study: NCT05504746
Drug: SHEN26 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
Study: NCT05504746
Drug: SHEN26 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose.
Study: NCT05504746
Drug: SHEN26 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days.
Study: NCT04812483
Drug: standard therapy (without eltrombopag): HD-DXM
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
Study: NCT05713838
Drug: mFOLFOX-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
Study: NCT06133270
Drug: NNC0560-0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0560-0004, Oral administration (taken through the mouth)
Study: NCT06133270
Drug: Placebo (NNC0560-0004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
Study: NCT05019105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo
Study: NCT06388863
Drug: Healthy donor-derived FMT capsule
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with healthy donor-derived fecal microbiota transplantation in the form of oral capsules.
Study: NCT06388863
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules whose appearance and smell are identical as FMT capsules but contain milk powder